Investors Purchase Large Volume of Call Options on BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw some unusual options trading on Wednesday. Traders acquired 1,200 call options on the stock. This is an increase of 943% compared to the typical volume of 115 call options.

BioCryst Pharmaceuticals (NASDAQ BCRX) opened at $5.61 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53. The company has a market capitalization of $552.05, a price-to-earnings ratio of -8.77 and a beta of 3.05. BioCryst Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). The business had revenue of $8.76 million during the quarter, compared to analyst estimates of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. BioCryst Pharmaceuticals’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.16) earnings per share. research analysts predict that BioCryst Pharmaceuticals will post -0.71 EPS for the current fiscal year.

In other news, CMO William P. Sheridan sold 64,310 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $4.72, for a total value of $303,543.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 5.80% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 19.9% in the second quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after purchasing an additional 996,052 shares in the last quarter. RA Capital Management LLC raised its stake in shares of BioCryst Pharmaceuticals by 47.9% in the second quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after purchasing an additional 1,672,447 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of BioCryst Pharmaceuticals in the third quarter valued at $23,762,000. State Street Corp raised its stake in shares of BioCryst Pharmaceuticals by 72.0% in the second quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock valued at $21,736,000 after purchasing an additional 1,636,909 shares in the last quarter. Finally, VHCP Management II LLC raised its stake in shares of BioCryst Pharmaceuticals by 27.9% in the third quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock valued at $16,587,000 after purchasing an additional 690,290 shares in the last quarter. Institutional investors and hedge funds own 84.69% of the company’s stock.

Several equities research analysts have recently weighed in on BCRX shares. Barclays started coverage on BioCryst Pharmaceuticals in a research report on Wednesday, December 20th. They issued an “equal weight” rating and a $6.00 price objective for the company. Royal Bank of Canada started coverage on BioCryst Pharmaceuticals in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $6.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $8.63.

WARNING: “Investors Purchase Large Volume of Call Options on BioCryst Pharmaceuticals (BCRX)” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/06/investors-purchase-large-volume-of-call-options-on-biocryst-pharmaceuticals-bcrx.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply